Alpha 2.0
Login Register
» Authors » Anna Beutler

Anna Beutler

Explore the profile of Anna Beutler including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 1050
Followers 0
Related Specialties
Rheumatology
Cardiology & Vascular Diseases
Pharmacology
Top 10 Co-Authors
Arthur Kavanaugh
Desiree van der Heijde
Gerald G Krueger
Philip Mease
Iain B McInnes
Michael Mack
Dafna Gladman
Antonio Abbate
Sudha Visvanathan
Benjamin Hsu
Published In
Arthritis Rheum
Ann Rheum Dis
Arthritis Care Res (Hoboken)
J Rheumatol
Am Heart J
Affiliations
Soon will be listed here.
Recent Articles
1.
Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
Lin D, Klein A, Cella D, Beutler A, Fang F, Magestro M, et al.
BMC Cardiovasc Disord . 2021 Apr; 21(1):201. PMID: 33882846
Background: Impact of recurrent pericarditis (RP) on patient health-related quality of life (HRQoL) was evaluated through qualitative patient interviews and as an exploratory endpoint in a Phase 2 trial evaluating...
2.
Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial
Klein A, Lin D, Cremer P, Nasir S, Luis S, Abbate A, et al.
Heart . 2020 Nov; PMID: 33229362
Objective: Recurrent pericarditis (RP) incurs significant morbidity. Rilonacept inhibits both interleukin-1 alpha (IL-1α) and IL-1β; these cytokines are thought to play a major role in RP. This phase II study...
3.
RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis
Klein A, Imazio M, Brucato A, Cremer P, LeWinter M, Abbate A, et al.
Am Heart J . 2020 Sep; 228:81-90. PMID: 32866928
Recurrent pericarditis (RP) occurs in 15% to 30% of patients following a first episode, despite standard treatment with nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids; many patients become dependent on corticosteroids....
4.
Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America
Vecchie A, Chiabrando J, Dell M, Bonaventura A, Mauro A, Wohlford G, et al.
Chest . 2020 Jul; 158(6):2556-2567. PMID: 32717264
Background: Acute pericarditis is the most common presentation of pericardial diseases. Although generally benign, complications such as constrictive pericarditis, cardiac tamponade, and recurrence can occur. Research Question: What are the...
5.
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Smolen J, Agarwal S, Ilivanova E, Xu X, Miao Y, Zhuang Y, et al.
Ann Rheum Dis . 2017 Jan; 76(5):831-839. PMID: 28087506
Objective: Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a...
6.
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study
Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger G, et al.
Arthritis Care Res (Hoboken) . 2015 Mar; 68(2):267-74. PMID: 25779603
Objective: To evaluate long-term outcomes in psoriatic arthritis (PsA) patients who achieved or did not achieve minimal disease activity (MDA) through 5 years of golimumab treatment in the GO-REVEAL trial....
7.
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
Kavanaugh A, McInnes I, Mease P, Krueger G, Gladman D, van der Heijde D, et al.
Ann Rheum Dis . 2014 Apr; 73(9):1689-94. PMID: 24748630
Objectives: Assess golimumab's long-term efficacy/safety in psoriatic arthritis (PsA). Methods: Adults with active PsA (≥3 swollen and tender joints, active psoriasis) were randomly assigned to subcutaneous placebo, golimumab 50 mg,...
8.
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial
Kavanaugh A, McInnes I, Krueger G, Gladman D, Beutler A, Gathany T, et al.
Arthritis Care Res (Hoboken) . 2013 May; 65(10):1666-73. PMID: 23666608
Objective: To evaluate the effect of golimumab on physical function, health-related quality of life (HRQOL), and productivity in psoriatic arthritis (PsA). Methods: GO-REVEAL was a multicenter, randomized, placebo-controlled study. Adult...
9.
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
Braun J, Baraliakos X, Hermann K, Deodhar A, van der Heijde D, Inman R, et al.
Ann Rheum Dis . 2013 May; 73(6):1107-13. PMID: 23644549
Objective: To evaluate radiographic progression in patients with ankylosing spondylitis (AS) receiving two different doses of the tumour necrosis factor antagonist golimumab. Methods: 356 patients with AS were randomly assigned...
10.
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
Kavanaugh A, McInnes I, Mease P, Krueger G, Gladman D, van der Heijde D, et al.
Ann Rheum Dis . 2012 Nov; 72(11):1777-85. PMID: 23161902
Objectives: To assess long-term golimumab efficacy/safety in patients with active psoriatic arthritis (PsA). Methods: Adult PsA patients (≥3 swollen, ≥3 tender joints, active psoriasis) were randomly assigned to subcutaneous injections...